Notably, some studies demonstrated that the overexpression of DEPDC1B could be used as a prognostic biomarker to predict the outcomes of patients with prostate and non-small cell lung cancers (Yang et al., 2014; Bai et al., 2017). The gene discussed is DEPDC1B; the disease is non-small cell lung carcinoma.